NCT03017833: Study of TAK-228 (MLN0128) in Combination With Metformin in Patients With Advanced Cancers

NCT03017833
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients who have a history of brain metastasis are eligible for the study provided they meet certain criteria- see trial for details
Exclusions: 
https://ClinicalTrials.gov/show/NCT03017833

Comments are closed.

Up ↑